Fig. 6: Evaluation of the protective efficacy of the GDIII-Ferritin nanoparticle vaccine.
a Schematic representation of the vaccination strategies and rabies virus challenge protocols for different groups of experimental mice. (n = 10/group). Group 1 (Mock) served as the negative control and received two subcutaneous immunizations with Freund’s adjuvant; Group 2 was the GDIII-Ferritin nanoparticle vaccine single-dose (30 μg, 0 d) group that received a single subcutaneous immunization; Group 3 was the GDIII-Ferritin nanoparticle vaccine single-dose (60 μg, 0 d) group that received a single subcutaneous immunization; Group 4 was the commercial rabies vaccine BRP single-dose (8.6 mg, 0 d) group that received a single subcutaneous immunization. Group 5 was the GDIII-Ferritin nanoparticle vaccine two-dose (30 μg/dose, 0 d and 7 d) group that received two subcutaneous immunizations; Group 6 was the commercial rabies vaccine BRP two-dose (8.6 mg/dose, 0 d and 7 d) group that received two subcutaneous immunizations. All the experimental mice underwent intracranial rabies virus challenge on day 14 post priming immunization. b Virus neutralizing antibody titers (VNATs) in the sera of mice within 28 days full-dose vaccine immunization (n = 5). Experiments were conducted independently in triplicates. Data represented as mean ± SEM and were analyzed using one-way ANOVA followed by Tukey’s multiple comparison post hoc test. ns (not significant), *p < 0.05, **p < 0.01, ****p < 0.0001. c Weight changes in mice during challenge with the rabies virus CVS-24 strain were recorded for 21 days. d The survival rates of the infected mice were calculated during 21 days post challenge. Source data are provided as a Source Data file.
